All lobbying filings

BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Lobbying for BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $280,000.00 expenses · posted Apr 20, 2026

Official filing document

Bills named in this filing 8

HR 7148
Consolidated Appropriations Act, 2026
S 2211
Special Diabetes Program Reauthorization Act of 2025
HR 5461
Special Diabetes Program Reauthorization Act of 2025
S 3064
Relief of Chronic Pain Act of 2025
S 4189
INSULIN Act of 2026
HR 5467
PAAT Act
S 3105
ISLET Act
HR 8018
ISLET Act

Lobbying activity 2

Budget/Appropriations

H.R.7148 - Consolidated Appropriations Act, 2026

Health Issues

S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 S. 3064 - the Relief of Chronic Disease Pain Act of 2026 S. 4189 - the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026 H.R. 5467 - the Patient Access to Autoimmune Treatments Act S. 3105 / H.R. 8018 - the Increase Support for Life-saving Endocrine Transplantation Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to NIH/FDA funding Issues pertaining to screening and early detection

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.